期刊文献+

帕金森病非运动症状相关性的研究 被引量:4

Cross-validation between non-motor symptoms and motor symptoms in Parkinson' s disease
原文传递
导出
摘要 目的 探讨帕金森病(PD)患者非运动症状(NMS)中抑郁、自主神经功能、认知功能、嗅觉、快速动眼睡眠障碍评分之间及其与运动症状的相关性.方法 采用PD综合评分量表(UPDRSⅢ)对44例原发性PD患者的运动症状进行评估;同时采用简易智力状况检查量表(MMSE)、17项汉密尔顿抑郁量表(HAMD-17)、PD自主神经功能量表(SCOPA-AUT)、睡眠障碍(RBD)量表和史尼芬16项嗅觉筛查量表(SS-16)对患者的NMS进行评分,与12例对照组比较,统计NMS之间及其与UPDRSⅢ之间的相关性.结果 PD组患者嗅觉障碍、抑郁程度、自主神经功能、快速动眼睡眠障碍均较对照组严重(P<0.01),而MMSE的评分比较差异则无统计学意义(P=0.804).此外,在PD组中,HAMD-17评分(r=0.447,P=0.004)、SCOPA-AUT评分(r=0.360,P =0.023)与UPDRSⅢ呈明显正相关;而在NMS之间SCOPA-AUT与RBD评分呈正相关(r =0.331,P =0.035);HAMD-17与MMSE评分呈明显负相关(r=-0.460,P=0.003,);与SCOPA-AUT呈正相关(r=0.394,P=0.011).结论 NMS已经成为影响PD患者生活质量的重要因素.NMS常伴随发生,其中抑郁、自主神经功能紊乱程度与运动症状的严重程度密切相关;自主神经功能紊乱与睡眠障碍的发生有一定相关性;PD患者抑郁的程度与其认知障碍和自主神经功能紊乱程度一致. Objective To explore the cross-validation between non-motor symptoms(depression,autonomic function,cognitive function,olfactory function and assessment of REM sleep behavior disorder) and motor symptoms in Parkinson's disease(PD).Methods Motor symptoms of 44 PD patients were assessed with UPDRSⅢ.The mini-mental state examination (MMSE),the 17-item Hamilton Rating Scale for Depression (HAMD-17),SCOPA-AUT Scales for Outcomes in Parkinson's disease-Autonomic,REM sleep behavior disorder(RBD) and 16-item odor identification test from Sniffin' Sticks(SS-16) were applied to study non-motor symptoms in PD patients and 12 healthy controls.Results A significant difference(P 〈 0.01) was achieved between controls and patients in the assessment of olfactory function by SS-16 scores,severity of depression by the HAMD-17 and automalic function by SCOPA-AUT and RBD scores although there was no significant difference in their MMSE (P =0.804) ; In addition,in PD patients,HAMD-17 (r =0.447,P =0.004) and SCOPA-AUT (r =0.360,P =0.023) were significantly positively related with the severity of PD.Furthermore,MMSE scores were decreased with severity of depression(r =-0.460,P =0.003) ; In addition,autonomic function was positively related to HAMD-17 (r =0.394,P =0.011).Conclusion NMS has become one of the important factors affecting the quality of life in PD.NMS are usually accompanied by each other; Depression and dysfunction of autonomic function are closely associated with progression of PD;RBD is related to autonomic function either.In addition,depression in PD is consistant with cognitive impairment and dysfunction of autonomic function.
出处 《临床内科杂志》 CAS 2013年第6期389-391,共3页 Journal of Clinical Internal Medicine
基金 国家自然科学基金面上资助项目(81071024、81171202)
关键词 帕金森病 非运动症状 Parkinson' r = 0. 447s disease Non-motor symptoms
  • 相关文献

参考文献14

  • 1陈思涵,李承晏.帕金森病抑郁[J].临床内科杂志,2011,28(12):804-806. 被引量:1
  • 2Chen W,Chen S,Kang WY,et al.Application of odor identification test in Parkinson's disease in China:a matched case-control study.J Neurol Sci,2012,316:47-50.
  • 3Chaudhuri KR,Martinez-Martin P,Schapira AH,et al.International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease:the NMSQuest study.Mov Disord,2006,21:916-923.
  • 4Jasinska-Myga B,Putzke JD,Wider C,et al.Depression in Parkinson's disease.Can J Neurol Sci,2010,37:61-66.
  • 5Pankratz N,Marder KS,Halter CA,et al.Clinical correlates of depressive symptoms in familial Parkinson 's disease.Mov Disord,2008,23:2216-2223.
  • 6Fernandez HH,See RH,Gary MF,et al.Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance.J Geriatr Psychiatry Neurol,2009,22:223-227.
  • 7Starkstein SE,Merello M,Jorge R,et al.A validation study of depressive syndromes in Parkinson's disease.Mov Disord,2008,23:538-546.
  • 8张东伟.舍曲林治疗帕金森病抑郁患者的疗效观察[J].中国医师杂志,2011,13(6):854-855. 被引量:8
  • 9Larsen JP.Sleep disorders in Parkinson's disease.Adv Neurol,2003,91:329-334.
  • 10Saper CB,Chou TC,Scammell TE.The sleep switch:hypothalamic control of sleep and wakefulness.Trends Neurosci,2001,24:726-731.

二级参考文献41

  • 1Barone P. Treatment of depressive symptoms in Parkinson's dis- ease. Eur J Neurol, 2011,18 Suppl 1:11-15.
  • 2McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychia- try, 2003,54 ( 3 ) : 363-375.
  • 3Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol, 2001,24 (4) : 221-227.
  • 4van de Vijver DA, Roos RA, Jansen PA, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinso- nian drug treatment in patients on levodopa. Br J Clin Pharmacol, 2002,54(2) :168-170.
  • 5Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treat- ment of depressive disorders in patients with Parkinson~s disease. Neurol Sci, 2008,29 (6) :391-395.
  • 6Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Motor changes during sertraline treatment in depressed patients with Par- kinson~ disease. Eur J Neuro1,2008,15 (9) :953-959.
  • 7Nilsson FM, Kessing LV, Sorensen TM, et al. Major depressive disorder in Parkinson' s disease : a register-based study. Acta Psychiatr Scand, 2002,106:202-211.
  • 8Ring HA, Bench C J, Trimble MR, et al. Depression in Parkinson' s dis- ease. A Positron emission study. Bri J Psychiatry, 1994,165:333-339.
  • 9Storeh A, Ebersbaeh G, Fuehs G, et al. Depression in Parkinson' s dis- ease. Part 1 :epidemiology, signs and symptoms, pathophysiology and di- agnosis. Fortschr Neurol Psyehiatr, 2008,76:715-724.
  • 10Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of preva- lence studies of depression in Parkinson' s disease. Mov Disord, 2008, 23:183-189.

共引文献7

同被引文献50

  • 1张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:615
  • 2Cipriani S,Chen X,Schwarzschild MA.Urate:a novel biomarker of Parkinson' s disease risk,diagnosis and prognosis[J].Biomark Med,2010,4(5):701-712.
  • 3Weisskopf MG,OReilly E,Chen H,et al.Plasma urate and risk of Parkinson' s disease[J].Am J Epidemio1,2007,166 (5):561-567.
  • 4Schlesinger I,Schlesinger N.Uric acid in Parkinson' s disease[J].Mov Disord,2008,23 (12):1653-1657.
  • 5Fitzmaurice PS,Ang L,Guttman M,et al.Nigral glutathione deficiency is not specific for idiopathic Parkinson' s disease[J].Mov Disord,2003,18(9):969-976.
  • 6Andreadou E,Nikolaou C,Goumaras F,et al.Serum uric acid levels in patients with Parkinson ' s disease:their relationship to treatment and disease duration[J].Clin Neurol Neurosurg,2009,111 (9):724-728.
  • 7De Vera M,Rahman MM,Rankin J,et al.Gout and the risk of Parkinson' s disease:a cohort study[J].Arthritis Rheum,2008,59 (11):1549-1954.
  • 8Farr SA,Poon HF,Dogrukol-AkD,et al.The antioxidants alpha lipoic acid and N-acetylcysteine reverse memory impairment and antioxidative stress in aged SAMP8 mice[J].J Neurochem,2003,84 (5):1173-1183.
  • 9Ascherio A,LeWitt PA,Xu K,et al.Urate as a predictor of the rate of clinical decline in Parkinson disease[J].Arch Neuro1,2009,66 (12):1460-1468.
  • 10戴光政,刘洋,张雅西,陈文玉.森福罗治疗帕金森病副作用的系统评价[J].中国社区医师(医学专业),2009,11(9):18-19. 被引量:3

引证文献4

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部